Answers are grounded in this paper and cite their sources.
Cases of pulmonary arterial hypertension (PAH) were reported after bosutinib exposure, most often in patients with pre-existing dasatinib-induced PAH, which relapsed following switch to bosutinib. Whether bosutinib by itself could induce PAH remains unclear. We retrospectively analysed incident cases of PAH in patients treated with bosutinib between 2013 and 2024, as well as their exposure to other BCR ABL tyrosine kinase inhibitors, using data from the French pulmonary hypertension (PH) registry and the French national health care database. 12 cases of bosutinib-associated PAH in patients with chronic myeloid leukaemia were identified in the PH registry (8 females; median age, 67 years), 11 of whom had prior dasatinib exposure, with history of dasatinib-induced cardiopulmonary complications in 10/11 cases including PAH ( n = 4), pleural or pericardial effusion ( n = 4) or both ( n = 2). Only 1 case occurred in a patient with severe chronic obstructive pulmonary disease and no prior dasatinib exposure. Despite often severe clinical (New York Heart Association functional class III or IV in 8 patients) and haemodynamic (median pulmonary vascular resistance, 5.9 [min-max, 2.2–11.9] Wood Units) involvement at PAH diagnosis, significant improvements were observed after bosutinib discontinuation, combined with PAH approved therapies in most cases. Sixteen cases of bosutinib-associated PAH were identified from the SNDS database (2.37 [95% confidence interval, 1.35 to 3.85] per 1000 person-years), including 13 with prior dasatinib exposure. Our findings do not provide evidence that bosutinib alone can induce de novo PAH, but support a role for bosutinib in triggering or worsening pulmonary vascular injury in patients previously exposed to dasatinib. Physicians should be aware of this rare but severe complication of bosutinib for close monitoring and appropriate management, particularly in patients with prior history of dasatinib induced-cardiopulmonary complications.
No takes yet. Share an insight, caveat, or question.
Iván et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: